Dr Pasquier is a recognized expert in oncopharmacology and pediatric tumors of the nervous system. After completing his PhD in 2006 at Aix Marseille University, he joined the team of Prof Maria Kavallaris at the Children’s Cancer Institute Australia in Sydney, where he led a research group for 8 years. In 2014, he moved back to France after securing a Marie Curie Fellowship from the European Research Council, and was recruited at CNRS as a permanent researcher in 2016 (ranked 1st, section 28) and joined the Cancer Research Center of Marseille (CRCM). In 2018, he co-founded React-4Kids, the French national network of basic and translational research in pediatric oncology (400+ members). In 2020, his research achievements and public engagement activities were recognized by the Bronze Medal of CNRS. Finally, he co-leads the Reverse Molecular Pharmacology in Pediatric Oncology (REMAP-4Kids) Team at CRCM since January 2024.
To date, Dr Pasquier has co-authored 83 peer-reviewed publications (H index 32) and secured competitive funding as principal investigator and member of large consortia. His research work is based on reverse molecular pharmacology, which consists in using existing drugs as molecular tools to study the biology of pediatric cancers. This work has already led to several clinical trials, including the ongoing PROVIN phase I/II trial (NCT02897986), investigating the potential of anti-hypertensive drug propranolol in combination with metronomic chemotherapy in children with refractory solid tumors.
